Sökning: onr:"swepub:oai:DiVA.org:uu-124897" >
High-dose therapy a...
High-dose therapy and autologous stem-cell transplantation in angioimmunoblastic lymphoma : complete remission at transplantation is the major determinant of Outcome-Lymphoma Working Party of the European Group for Blood and Marrow Transplantation
-
Kyriakou, Charalampia (författare)
-
Canals, Carmen (författare)
-
Goldstone, Anthony (författare)
-
visa fler...
-
Caballero, Dolores (författare)
-
Metzner, Bernd (författare)
-
Kobbe, Guido (författare)
-
Kolb, Hans-Jochem (författare)
-
Kienast, Joachim (författare)
-
Reimer, Peter (författare)
-
Finke, Jurgen (författare)
-
- Öberg, Gunnar (författare)
- Uppsala universitet,Institutionen för medicinska vetenskaper,Blodsjukdomar
-
Hunter, Ann (författare)
-
Theorin, Niklas (författare)
-
Sureda, Anna (författare)
-
Schmitz, Norbert (författare)
-
visa färre...
-
(creator_code:org_t)
- 2008
- 2008
- Engelska.
-
Ingår i: Journal of Clinical Oncology. - 0732-183X .- 1527-7755. ; 26:2, s. 218-224
- Relaterad länk:
-
https://urn.kb.se/re...
-
visa fler...
-
https://doi.org/10.1...
-
visa färre...
Abstract
Ämnesord
Stäng
- PURPOSE: Patients with angioimmunoblastic T-cell lymphoma (AITL) have poor prognoses with current conventional chemotherapy. The aim of this study was to evaluate the effect of high-dose therapy (HDT) followed by autologous stem-cell transplantation (ASCT) on patients with AITL. PATIENTS AND METHODS: We report a retrospective, multicenter study of 146 patients with AITL who received ASCT. The source of the stem cells was peripheral blood in 143 patients. The conditioning regimen varied, and 74% of the patients received carmustine and 1,3-bis(2-chloroethyl)-1-nitrosourea; etoposide; ara-C; and melphalan chemotherapy. RESULTS: After a median follow-up of 31 months (range, 3 to 174 months), 95 patients (65%) remained alive, and 51 patients (35%) died. Forty-two patients died as a result of disease progression, and nine died as a result of regimen-related toxicity. The cumulative incidence of nonrelapse mortality was 5% and 7% at 12 and 24 months, respectively. The actuarial overall survival (OS) was 67% at 24 months and 59% at 48 months. The cumulative incidence of relapse was estimated at 40% and 51% at 24 and 48 months, respectively. Disease status at transplantation was the major factor that impacted outcome. Patients who received a transplant during first complete remission (CR) had significantly superior progression-free survival and OS. The estimated PFS rates for patients who received their transplants in CR were 70% and 56% at 24 and 48 months, respectively; 42% and 30% for patients with chemotherapy-sensitive disease at those time points, respectively; and 23% at both time points for patients with chemotherapy-refractory disease. CONCLUSION: This study shows that HDT and ASCT offers the possibility of long-term disease-free survival to patients with AITL. Early transplantation is necessary to achieve optimal results.
Nyckelord
- MEDICINE
- MEDICIN
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Kyriakou, Charal ...
-
Canals, Carmen
-
Goldstone, Antho ...
-
Caballero, Dolor ...
-
Metzner, Bernd
-
Kobbe, Guido
-
visa fler...
-
Kolb, Hans-Joche ...
-
Kienast, Joachim
-
Reimer, Peter
-
Finke, Jurgen
-
Öberg, Gunnar
-
Hunter, Ann
-
Theorin, Niklas
-
Sureda, Anna
-
Schmitz, Norbert
-
visa färre...
- Artiklar i publikationen
-
Journal of Clini ...
- Av lärosätet
-
Uppsala universitet